Pegcetacoplan was the first proximal complement inhibitor approved for PNH; by blocking C3 and C3b, pegcetacoplan prevents both IVH and EVH, and has demonstrated long-term safety and treatment benefits in patients with PNH. This evidence concerns the gene C3 and paroxysmal nocturnal hemoglobinuria.